Versameb CEO Talks RNA Spotlight And Biotech Culture
An Interview With Klaas Zuideveld
As part of In Vivo’s Rising Leaders series, Versameb CEO Klaas Zuideveld discusses the next-generation RNA company’s technology and target indications. He also shares more about his career journey, lessons learned, and gives insight into the contrasting business cultures within big pharma and biotech.
You may also be interested in...
After a baptism of fire during the coronavirus pandemic, mRNA vaccine technology has earned its stripes. In less than a year, mRNA vaccines have been catapulted from interesting pipeline prospects to game-changers in the fight against COVID-19. But what does this success mean for the future of the technology?
A selection of articles you might have missed from July 2021, including exclusive interviews with industry leaders and a deep dive into the RNA therapy pipeline.
With digital therapies and devices seeing widespread adoption in response to lockdown limitations during the COVID-19 pandemic, Kaiku Health is in a strong position to expand its patient monitoring software. CEO Lauri Sippola spoke with In Vivo about the platform and the company’s plans for 2021 and beyond.